Researcher calls for one-person trials for personalized medicine

Researcher calls for one-person trials for personalized medicine

Publication date: Jun 05, 2020

This is still highly relevant today, since most drugs on the market are “one size fits all,” meaning patients with the same condition often receive the same dose, even though studies show that this is only optimal for a fraction of them.

By identifying the right drug, in the right dose, at the right time for each patient, precision medicine has the potential to make the healthcare system more efficient and to treat patients more effectively.

Essentially, precision medicine combines a patient’s genetic data with clinical, environmental and lifestyle information to guide decisions for the optimal prevention, diagnosis, and treatment of conditions.

I assume that the future of pharmacogenomics and precision medicine will be built on a critical mass of interested and committed stakeholders-including patients and clinicians informed enough to ask for it.

The patients here partner closely with physicians and other stakeholders, and are involved in treatment decisions on their own health issues.

A cohort as initial spark Since genetic differences in pharmacogenes account for a quarter to half of an individual’s response to medicine, such under-representation could mean that drugs may work less effectively in women than in men.

This will empower the individuals to be more involved in their treatment decisions, and to benefit from the advantages of precision medicine and pharmacogenomics, from better treatment options and fewer side effects.

Concepts Keywords
Cardiovascular Disease Personalized medicine
CC0 Clinical trial
Clinical Practice Guidelines Precision medicine
Clinical Trials Clinical research
Cohort Healthcare costs
Critical Mass Diseases
Digestive Diseases Health
ETH Zurich Articles
Fair Dealing Genomics
Genetic Pharmacology
Genome Pharmacogenomics
Healthcare Pharmacy
Hepatitis Evidence-based medicine
HIV
Incidence
Kidney
Marginalized Groups
Medicine
Mental Health
Metabolism
Neurological
Paracelsus
Pharmacogenomics
Physician
Poison
Precision Medicine
Swiss

Semantics

Type Source Name
drug DRUGBANK Ethionamide
drug DRUGBANK Nonoxynol-9
disease MESH lifestyle
disease MESH diagnosis
pathway REACTOME Metabolism
disease MESH men
disease MESH cardiovascular disease
disease MESH hepatitis
disease MESH chronic kidney disease
drug DRUGBANK Tropicamide

Leave a Comment

Your email address will not be published. Required fields are marked *